Harvard Bioscience
HBIO | NASDAQ
$8.91
-$0.48 (-5.11%)
At close: Nov 16, 2026, 4:00 PM ET
$9.26
+$0.35 (+3.91%)
After-hours:
Nov 16, 2026, 4:24 PM ET
Harvard Bioscience Company Profile
Company profile explainedCompany Profile
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| John Duke | President, CEO, Director & Member of Scientific Advisory Board |
| David Panzarella | Senior Vice President of Commercial |
| David Sirois | Director of Corporate Accounting & SEC Reporting |
| Kathryn Flynn | Corporate Controller |
| Lori Packer | Vice President of Global People Operations |
| Mark T. Frost | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 22, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jun 12, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
| Jun 10, 2026 | S-8 | Filing |
Harvard Bioscience
| Country | United States |
| IPO Date | Dec 7, 2000 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 328 |
| CEO | John D. Duke |
Contact Details
84 October Hill Road Holliston,
Massachusetts 01746 United States
Stock Details
| Ticker Symbol | HBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001123494 |
| CUSIP Number | 416906204 |
| ISIN Number | US4169062043 |
| SIC Code | 3826 |
Add to Watchlist
Select watchlists to add or remove HBIO